Isoplexis's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Isoplexis (ISO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Isoplexis vs Its Competitors
- TTM: Trailing 12-month revenue of 17M vs -M combined for its competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-19.9% annualized vs trailing 12 months).
- Peer revenue share: Isoplexis accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ISO Sales vs. its Competitors, Q4 2022
Isoplexis generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
For context: the Laboratory Analytical Instruments industry grew revenue 13.3% year over year, combined, vs -40.3% for Isoplexis. Isoplexis's share of combined industry revenue moved from 0.06% to 0.03%, a loss of 0.03 percentage points.
Isoplexis's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Isoplexis Corporation | - | No | No | Yes |
| High-Confidence Competitors (9) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ISO Stock Performance relative to its Competitors
ISO Stock Performance relative to High-Confidence Competitors
Isoplexis's Competitors Named by the Company
Competitive relationships identified from Isoplexis reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Omniab Inc | Company report | 85% |
| Abcellera Biologics Inc | Company report | 85% |
| Nautilus Biotechnology Inc | Company report | 85% |
| Agilent Technologies inc | Company report | 85% |
| 908 Devices inc | Company report | 85% |
| Akoya Biosciences Inc | Company report | 85% |
| T2 Biosystems Inc | Company report | 85% |
| CNFR | Company report | 85% |
| Absci Corp | Company report | 85% |
| Presurance Holdings Inc | Company report | 85% |
| Revvity Inc | Company report | 85% |
| Avantor Inc | Company report | 85% |
| Bio rad Laboratories Inc | Company report | 85% |
| Mettler toledo International Inc | Company report | 85% |
| Cytek Biosciences Inc | Company report | 85% |
| Standard Biotools Inc | Company report | 85% |
| Telesis Bio Inc | Company report | 85% |
| Illumina Inc | Company report | 85% |
| Singular Genomics Systems Inc | Company report | 85% |
| Astrotech Corp | Company report | 85% |
| Danaher Corporation | Company report | 85% |
| 10x Genomics Inc | Company report | 85% |
| Harvard Bioscience Inc | Company report | 85% |
| Thermo Fisher Scientific Inc | Company report | 85% |
| Olink Holding Ab publ | Company report | 85% |
Company report basis, confidence, active dates and source counts for Isoplexis's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.